异丙肾上腺素结构式
|
常用名 | 异丙肾上腺素 | 英文名 | Isoprenaline |
---|---|---|---|---|
CAS号 | 6700-39-6 | 分子量 | 211.258 | |
密度 | 1.2±0.1 g/cm3 | 沸点 | 417.5±40.0 °C at 760 mmHg | |
分子式 | C22H40N2O12S | 熔点 | 130°C | |
MSDS | N/A | 闪点 | 179.7±17.9 °C |
中文名 | 硫酸异丙肾上腺素 |
---|---|
英文名 | DL-Isoproterenol sulfate dihydrate |
中文别名 | 硫酸DL-异丙肾上腺素二水 | 异丙肾上腺素 |
英文别名 | 更多 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 417.5±40.0 °C at 760 mmHg |
熔点 | 130°C |
分子式 | C22H40N2O12S |
分子量 | 211.258 |
闪点 | 179.7±17.9 °C |
精确质量 | 211.120850 |
PSA | 246.88000 |
LogP | 0.25 |
外观性状 | 白色细结晶粉末 |
蒸汽压 | 0.0±1.0 mmHg at 25°C |
折射率 | 1.579 |
储存条件 | 2-8°C |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:12 3.氢键受体数量:14 4.可旋转化学键数量:8 5.互变异构体数量:27 6.拓扑分子极性表面积230 7.重原子数量:37 8.表面电荷:0 9.复杂度:268 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:2 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:5 |
更多 | 1. 性状:未确定 2. 密度(g/mL,25℃):未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(ºC):130 5. 沸点(ºC,常压):未确定 6. 沸点(ºC,15mmHg):未确定 7. 折射率(n20/D):未确定 8. 闪点(ºC):未确定 9. 比旋光度(º):未确定 10. 自燃点或引燃温度(ºC):未确定 11. 蒸气压(mmHg,217ºC):未确定 12. 饱和蒸气压(kPa,25ºC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(ºC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:未确定 |
危害码 (欧洲) | Xn |
---|---|
风险声明 (欧洲) | R22:Harmful if swallowed. |
安全声明 (欧洲) | S16-S36/37-S45 |
危险品运输编码 | UN 1544 6.1/PG 3 |
WGK德国 | 1 |
RTECS号 | EV6475000 |
Exchange protein directly activated by cAMP mediates slow delayed-rectifier current remodeling by sustained β-adrenergic activation in guinea pig hearts.
Circ. Res. 114(6) , 993-1003, (2014) β-Adrenoceptor activation contributes to sudden death risk in heart failure. Chronic β-adrenergic stimulation, as occurs in patients with heart failure, causes potentially arrhythmogenic reductions in... |
|
Protein kinetic signatures of the remodeling heart following isoproterenol stimulation.
J. Clin. Invest. 124(4) , 1734-44, (2014) Protein temporal dynamics play a critical role in time-dimensional pathophysiological processes, including the gradual cardiac remodeling that occurs in early-stage heart failure. Methods for quantita... |
|
Chlorogenic acid prevents isoproterenol-induced hypertrophy in neonatal rat myocytes.
Toxicol. Lett. 226(3) , 257-63, (2014) Cardiac hypertrophy is an independent risk factor for cardiovascular disease and its subsequent progression to heart failure represents a major cause of morbidity and mortality in the world. CGA is an... |
3,4-Dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol |
Aerotrol |
4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol |
(±)-Isoproterenol |
1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)- |
3,4-Dihydroxy-α-(isopropylaminomethyl)-benzyl alcohol |
a-(Isopropylaminomethyl)protocatechuyl Alcohol |
isoproterenol |
MFCD00013139 |
4-{1-Hydroxy-2-[(1-methylethyl)amino]ethyl}benzol-1,2-diol |
4-{1-hydroxy-2-[(1-méthyléthyl)amino]éthyl}benzène-1,2-diol |
Benzyl alcohol, 3,4-dihydroxy-α-((isopropylamino)methyl)-, (-)- |
4-[1-Hydroxy-2-(isopropylamino)ethyl]-1,2-benzenediol |
Protocatechuyl alcohol, α-(isopropylaminomethyl)- |
Isomenyl |
Isupren |
(±)-Isoprenaline |
4-[1-Hydroxy-2-(isopropylamino)ethyl]benzene-1,2-diol |
isoprenaline sulfate |
Aleudrin |
4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol |
N-Isopropyl-b-dihydroxyphenyl-b-hydroxyethylamine |
1,2-Benzenediol, 4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]- |
4-(1-Hydroxy-2-(isopropylamino)ethyl)benzene-1,2-diol |
4-[1-Hydroxy-2-[(1-methylethyl)amino]ethyl]-1,2-benzenediol |
3,4-Dihydroxy-a-[(isopropylamino)methyl]benzyl Alcohol |
AEROLONE |